Associated Papers
Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study.
Soeria-Atmadja S et al.
British Journal of Clinical Pharmacology, 2025
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Redefining copy number variation and single-nucleotide polymorphism counting via novel concepts based on recent PCR enhancements.
Kim JJ et al.
Biochemical and Biophysical Research Communications, 2024
PharmVar GeneFocus: CYP2A6.
Langlois AWR et al.
Clinical Pharmacology and Therapeutics, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
G-quadruplex forming sequences in the genes coding for cytochrome P450 enzymes and their potential roles in drug metabolism.
Saad M et al.
Biochimie, 2023
Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.
Perez-Paramo YX et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2023
Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R et al.
Pharmacogenomics, 2023
CYP2A6 gene polymorphism and severity of coronary atherosclerosis in Indonesian male smokers: A pilot study.
Mappangara I et al.
Medicine, 2022
Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease.
Cacabelos R et al.
Pharmaceuticals (basel, Switzerland), 2021
Pharmacogenetic considerations in the treatment of co-infections with HIV/AIDS, tuberculosis and malaria in Congolese populations of Central Africa.
Pallerla SR et al.
International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases, 2021
Genetic polymorphisms of pharmacogenomic VIP variants in the Dai population from Yunnan province.
Cheng Y et al.
Molecular Genetics & Genomic Medicine, 2020
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
Haas DW et al.
Pharmacogenetics and Genomics, 2020
From Genotype to Phenotype: Content and Activities of Cytochromes P450 2A6 in Human Liver In Vitro and Predicted In Vivo.
Fang Y et al.
The Journal of Pharmacology and Experimental Therapeutics, 2020
Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.
Borrie AE et al.
Breast Cancer Research and Treatment, 2018
Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana.
Vujkovic M et al.
The Pharmacogenomics Journal, 2018
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.
Haas DW et al.
Pharmacogenetics and Genomics, 2018
Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.
Hiratsuka M et al.
Drug Metabolism and Pharmacokinetics, 2018
Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety.
Tucci JD et al.
Pharmacogenetics and Genomics, 2018
Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population.
Ezzeldin N et al.
Bmc Cancer, 2018
Effect of P450 Oxidoreductase Polymorphisms on the Metabolic Activities of Ten Cytochrome P450s Varied by Polymorphic CYP Genotypes in Human Liver Microsomes.
Fang Y et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 2018
Influence of vitamin intake and MTHFR polymorphism on the levels of DNA damage in tobacco farmers.
Fernandes SP et al.
International Journal of Occupational and Environmental Health, 2017
Genetic polymorphisms in CYP2A6 are associated with a risk of cigarette smoking and predispose to smoking at younger ages.
Pérez-Rubio G et al.
Gene, 2017
Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.
Mollan KR et al.
The Journal of Infectious Diseases, 2017
Phenome-wide association study for CYP2A6 alleles: rs113288603 is associated with hearing loss symptoms in elderly smokers.
Polimanti R et al.
Scientific Reports, 2017
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.
Bertholee D et al.
Clinical Pharmacokinetics, 2017
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
Jeong JH et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017
Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.
López-Flores LA et al.
Excli Journal, 2017
Disease burden and the role of pharmacogenomics in African populations.
Mpye KL et al.
Global Health, Epidemiology and Genomics, 2017
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting.
Fogli S et al.
Journal of Pharmaceutical and Biomedical Analysis, 2016
Effect of Genetic Polymorphisms and Long-Term Tobacco Exposure on the Risk of Breast Cancer.
Verde Z et al.
International Journal of Molecular Sciences, 2016
Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.
Leger P et al.
Pharmacogenetics and Genomics, 2016
CYP2A6 Longitudinal Effects in Young Smokers.
Cannon DS et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco, 2016
Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations.
Jittikoon J et al.
Journal of Human Genetics, 2016
Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.
Medhasi S et al.
Neuropsychiatric Disease and Treatment, 2016
Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
Olagunju A et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2015
Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Sinxadi PZ et al.
British Journal of Clinical Pharmacology, 2015
PharmGKB summary: Efavirenz pathway, pharmacokinetics.
McDonagh EM et al.
Pharmacogenetics and Genomics, 2015
A Global Health Diagnostic for Personalized Medicine in Resource-Constrained World Settings: A Simple PCR-RFLP Method for Genotyping CYP2B6 g.15582C>T and Science and Policy Relevance for Optimal Use of Antiretroviral Drug Efavirenz.
Evans J et al.
Omics : a Journal of Integrative Biology, 2015
Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2015
Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.
Haas DW et al.
Current Opinion in Hiv and Aids, 2015
Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.
Olagunju A et al.
Clinical Pharmacology and Therapeutics, 2015
Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations.
Kim JH et al.
Archives of Pharmacal Research, 2015
CYP2A6 Polymorphisms May Strengthen Individualized Treatment for Nicotine Dependence.
Akrodou YM
Scientifica, 2015
A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism.
Loukola A et al.
Plos Genetics, 2015
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
Haas DW et al.
The Journal of Antimicrobial Chemotherapy, 2014
High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.
Aklillu E et al.
Omics : a Journal of Integrative Biology, 2014
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
Sarfo FS et al.
The Journal of Antimicrobial Chemotherapy, 2014
The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
Bienvenu E et al.
Antiviral Research, 2014